October 14, 2022 - neurocare group
October 14, 2022 - neurocare group
In recent years, the non-invasive neurostimulation treatment, Transcranial Magnetic Stimulation, or ‘TMS’, has been gaining recognition as a viable and evidence-based medical alternative for patients suffering Depression who are not responding adequately to first line treatments, such as medication. The benefits of this treatment and how to best apply it, is being validated now in elderly populations.
Dr. Albino Oliveira-Maia, researcher, and director at NOVA Medical School in Portugal, runs a clinical unit focused on providing innovative mental health treatments for cancer patients and patients with Depression and OCD who have not been helped by other methods. Here they provide TMS in combination with other treatments and explore the positive effects and outcomes in a wide-ranging patient population, including those in geriatric care.
neurocare’s Dr Trevor Brown speaks with Dr Oliveira-Maia to learn more about his research and outlook for TMS and how the method can be improved and better utilized, such as the effects of ‘maintenance’ sessions and how well TMS works in elderly.
Albino is very active in pushing for TMS and other anti-depressant treatments to become part of standard care and discusses the current limitations of mental health care in Portugal and Europe at large, and how they can be improved.
Click here to watch the interview >
This interview may interest researchers, scientists, clinicians, and students working or studying in the field of mental healthcare. Although the conversation here centers around more scientific concepts, it may also interest a wider audience interested in learning more about the treatment approach of TMS in depression. (Medical interventions such as TMS should first be discussed with your GP.)
Other Articles
Jul. 22, 2024
Oct. 11, 2022
Feb. 14, 2024
Learn more about who we help, our therapeutic model and our global network of clinics.
Learn more about our DTP, innovative technologies and training academy for health professionals and researchers.
Copyright © neurocare group AG 2024